Phaseline

Companies › Kolon TissueGene

Kolon TissueGene: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TG-C (TissueGene-C)
Non-transduced human chondrocytes combined with irradiated transduced human GP2-293 cells
TGFB1Phase 3Degenerative Osteoarthritis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03203330TG-C (TissueGene-C)Phase 3Degenerative OsteoarthritisImmunologyJul 2024

Targets

TGFB1 (1)

Companies with the same targets

Bristol-Myers Squibb Sirnaomics FBD Biologics Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Bicara Therapeutics

Companies built like this

ALK-Abelló Doron Therapeutics UnicoCell Biomed medac Abeona Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.